Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
Multicentre, phase II, open-label, single-arm study evaluating the preliminary efficacy,
safety and tolerability of atezolizumab in association with palliative radiotherapy in adult
patients diagnosed with advanced (stage IV) NSCLC, irrespective of PD-L1 status, and who have
oligoprogressed to both immunotherapy with an anti PD-1 agent (e.g., pembrolizumab or
nivolumab) and 1 line of chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Oncology Institute of Southern Switzerland
Collaborators:
Clinical Trial Unit Ente Ospedaliero Cantonale Ente Ospedaliero Cantonale, Bellinzona Istituto Cantonale di Patologia